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Insomnia and somnolence in idiopathic RBD: a prospective
cohort study
Ronald B. Postuma1,2, Jean-François Gagnon2,3, Amelie Pelletier2 and Jacques Y. Montplaisir2,4
Although some sleep disorders are markers of prodromal Parkinson’s disease and dementia with Lewy bodies, it is unclear whether
insomnia and somnolence can predict disease. We assessed a large cohort of patients with idiopathic rapid eye movement sleep
behavior disorder and age/sex matched controls, comparing the Epworth sleepiness scale, the Insomnia Severity Index, the
Pittsburgh Sleep Quality Index, and polysomnographic variables. In those with repeated scales, we assessed change over time.
Finally, we assessed whether sleep abnormalities predicted defined neurodegenerative disease. The 151 patients (age = 65.9, 75%
male) completed sleep scales and were included. Epworth scores were similar between patients and controls (7.0+/−4.6 vs. 7.2
+/−4.7, p = 0.77), and did not progress with time (change = +0.46+/−2.1, p = 0.45). Epworth scores were similar between those who
developed neurodegenerative disease and those remaining disease-free (6.7+/−4.4 vs. 7.1+/−4.7, p = 0.70). Pittsburgh Index scores
were higher in patients than controls (7.2+/−3.8 vs. 4.9+/−3.4, p = 0.004), mainly driven by the sleep disturbance/medication
components (reflecting rapid eye movement sleep behavior disorder symptoms/treatment). Baseline Pittsburgh scores did not
predict conversion to neurodegeneration, although sleep duration increased over time in those converting to neurodegenerative
disease (+0.88+/−1.32 h, p = 0.014). Insomnia index scores were higher in patients than controls (10.0+/−5.5 vs. 6.35+/−4.66, p <
0.001), but declined over time (−1.43+/−5.09, p = 0.029) particularly in those converting to neurodegenerative disease. Finally, on
polysomnogram, those with increased tonic rapid eye movement had higher risk of developing defined neurodegenerative disease
(HR = 1.88, p = 0.039). In summary, we found that somnolence and insomnia do not predict neurodegeneration in idiopathic rapid
eye movement sleep behavior disorder. As neurodegeneration progresses through prodromal stages, patients may have increasing
sleep drive and duration.
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INTRODUCTION
Daytime somnolence and insomnia are common features of
neurodegenerative synucleinopathies. Insomnia, particularly sleep
maintenance insomnia, occurs in up to 50% of Parkinson’s disease
(PD) patients and is a common early feature of disease.1
Somnolence occurs in 30–40% of PD and 40–70% of dementia
with Lewy bodies (DLB), and becomes more common as disease
progresses.2 Although onset time varies, both sleep disorders can
be seen at diagnosis, suggesting that they may be present in
prodromal disease.
So far, however, evidence for somnolence and insomnia as
prodromal markers is limited. Two general population studies
reported that increased daytime sleep was associated with a 2–3
fold increased risk of developing PD in the future.3, 4 However,
studies of early untreated PD have generally failed to find
excessive daytime somnolence compared to controls.5, 6 For
insomnia, a single study suggested a possible mild increased in PD
risk (RR = 1.4) in those presenting to medical attention for
insomnia in the prior two years,7 but no other studies have
assessed whether insomnia predicts PD.
Idiopathic rapid eye movement (REM) sleep behavior
disorder (RBD) is the strongest known predictor of PD and
other synucleinopathies.8 Long-term studies suggest that over
80% of idiopathic RBD patients will eventually develop neurode-
generative synucleinopathy.9–11 Therefore, following patients with
idiopathic RBD allows a unique opportunity to directly observe the
prodromal stages of disease, and to test potential prodromal
markers. RBD patients have been used to establish predictive
value of many prodromal markers, including hyposmia, dopami-
nergic functional neuroimaging, impaired color vision, REM sleep
atonia loss, autonomic symptoms, EEG slowing and quantitative
motor testing.12–18 A single study of patients with idiopathic RBD
found that Epworth sleepiness scale (ESS) scores were higher than
healthy controls and predicted faster conversion to neurodegen-
eration in RBD.19 However, no other studies have assessed
whether insomnia or somnolence predict outcome in idiopathic
RBD.
Since 2004, we have been following a large cohort of
idiopathic RBD20 patients. As part of clinical follow-up, patients
completed sleep scales including the ESS, the insomnia severity
index (ISI), and the Pittsburgh Sleep Quality index (PSQI).
Therefore, in this study, we assessed whether insomnia and
somnolence severity could predict development of defined
neurodegenerative synucleinopathy in idiopathic RBD, and
measured the evolution of these sleep disorders during prodromal
stages in those who eventually developed neurodegenerative
disease.
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RESULTS
Participant characteristics
In total, we evaluated 158 patients with idiopathic RBD. The 151
patients had at least one baseline sleep analysis and were
included in this analysis. Mean age was 66.4+/−8.3, RBD duration
from symptom onset was 8.7+/−9.3 years, and 75% were male.
Mean age of controls was 68.9+/−8.5 and 74% were male.
Of the 151 included in this analysis, the 132 had at least one annual
follow-up examination, of whom 50 developed neurodegenerative
disease after a mean interval of 3.2+/−2.4 years from baseline
evaluation (range = 1–11 years). The 26 patients had a primary
diagnosis of dementia, of whom 24 had at least one cardinal
manifestation of parkinsonism and 15 had full International Parkinson
and Movement Disorders Society (MDS) parkinsonism criteria21 at
disease diagnosis. Twenty four had a primary diagnosis of parkinson-
ism, of whom 20 had PD and three had multiple system atrophy.
Epworth sleepiness scale
The 116 idiopathic RBD patients had a baseline ESS performed
(Table 1). This was conducted on average 2.6+/−2.1 years before
the most recent visit (for disease-free patients), or disease
diagnosis (convertors). The mean ESS score was similar between
idiopathic RBD patients (7.0+/−4.6) and controls (7.2+/−4.7, n = 57,
p = 0.77). The proportion with abnormal ESS also did not differ
(28.7% vs. 28.1%, p = 1.0)
104/116 patients had at least one prospective follow-up visit
(Fig. 1, Table 1). We found no difference in baseline ESS scores
between those who eventually converted and those still remain-
ing disease-free (6.7+/−4.4 in convertors vs. 7.1+/−4.7 in disease-
free, p = 0.70).
The ESS was repeated in 56 RBD patients at a mean interval (i.e.
first to most recent score) of 2.3 years (Table 2). We found no
change in ESS scores (average change = +0.07+/−3.1 points,
p = 0.99). Moreover, there was no progression in ESS scores over
time in those destined to develop disease (mean change = +0.46
+/−2.1 points, p = 0.45).
Insomnia severity index
A total of 111 patients had assessment of their ISI, conducted an
average of 2.6 years before last follow-up or disease diagnosis
(Table 1). Overall, the mean ISI score in patients with idiopathic
RBD was higher than controls (10.0+/−5.5 vs. 6.35+/−4.66, n = 54,
p < 0.001). The 48.7% of RBD patients had abnormal ISI compared
to 24.5% of controls (p = 0.004). When looking at specific items,
differences were more marked for general sleep disturbances/
worry/impact (i.e. questions 4–7) than for the direct insomnia
questions. Nevertheless, there was a modest significant increase in
sleep maintenance insomnia in RBD patients compared to controls
(questions 2+3 = 2.7+/−1.7 vs. 2.1+/−1.4, p = 0.043).
Of the 111 patients with ISI, 100 had at least one follow-up
examination (Fig. 1, Table 1). There was no difference in baseline
ISI between those who developed disease vs. those who remained
disease-free (10.4+/−5.9 vs. 10.0+/−5.4, p = 0.76). Neither was
there any difference in the scores of any single ISI item.
The 63 patients had a repeated ISI, at a mean interval of 3.0
years between first and most recent score (Table 2). We observed
a significant decline in ISI over time (mean change = −1.43+/−5.09,
p = 0.029), moving towards control values with time. Although this
declined both in those developing disease and those still disease-
free, this was more clearly seen in those with disease (−2.00 in
disease convertors vs. −1.16 in disease-free). When looking at
subcomponents of the ISI in all RBD patients, the score reduction
was primarily driven by questions related to sleep satisfaction/
worrying about sleep. However, there was a borderline decline in
sleep maintenance insomnia scores (questions 2 and 3) in those
who developed disease (change = −0.45+/−1.05 points, p = 0.083).
Table 1. Baseline sleep scale scores
Control Idiopathic RBD p Disease-free Converted p
Epworth Sleepiness Scale 7.2+/−4.7 (n= 57) 7.0+/−4.6 (n= 116) 0.77 7.1+/−4.7 (n= 71) 6.7+/−4.4 (n= 33) 0.70
Abnormal Epworth 28.7% 28.1% 1.0 27.8% 33.3% 0.65
Insomnia Severity Index Total 6.4+/−4.7 (n= 54) 10.0+/−5.5 (n= 111) <0.001 10.0+/−5.4 (n= 67) 10.4+/−5.9 (n= 63) 0.76
Abnormal ISI 24.5% 48.7% 0.004 50.8% 48.5% 1.0
Onset Insomnia 0.74+/−0.91 0.86+/−1.04 0.47 0.80+/−1.01 1.03+/−1.16 0.32
Maintenance Insomnia 2.11+/−1.39 2.66+/−1.67 0.036 2.71+/−1.59 2.64+/−1.78 0.83
Sleep Satisfaction 1.30+/−1.0 1.99+/−1.18 <0.001 2.0+/−1.19 2.14+/−1.21 0.59
Daytime Impact 0.94+/−0.90 1.51+/−1.21 0.003 1.57+/−1.26 1.45+/−1.12 0.64
QOL impact 0.56+/−0.75 1.30+/−1.10 <0.001 1.28+/−1.08 1.45+/−1.32 0.47
Worry about sleep 0.70+/−1.02 1.64+/−1.20 <0.001 1.63+/−1.15 1.76+/−1.32 0.63
Pittsburgh Sleep Quality Index Total 4.89+/−3.38 (n= 29) 7.18+/−3.80 (n= 111) 0.004 7.12+/−3.79 7.66+/−4.1 0.52
Abnormal PSQI 44.9% 68.5% 0.029 68.7% 70.6% 1.0
Bed Time 23:14+/−1:14 22:56+/−1:10 0.22 23:01+/−1:05 22:43+/−1:22 0.27
Wake Time 7:38+/−1:13 7:23+/−1:19 0.31 7:20+/−1:23 7:37+/−1:18 0.32
Sleep Duration (hours) 7.50+/−1.21 7.39+/−1.33 0.70 7.29+/−1.31 7.58+/−1.45 0.33
PSQI Subcomponents Sleep Latency 0.93+/−0.75 1.17+/−0.77 0.14 1.16+/−0.76 1.25+/−0.83 0.53
Sleep Quality 0.93+/−1.00 0.88+/−0.97 0.81 0.91+/−1.00 0.88+/−0.98 0.89
Sleep Duration 0.50+/−0.85 0.64+/−0.77 0.40 0.69+/−0.78 0.59+/−0.79 0.53
Sleep Inefficiency 0.40+/−0.85 0.56+/−0.90 0.39 0.54+/−0.88 0.72+/−1.02 0.38
Sleep Disturbance 1.21+/−0.56 1.49+/−0.65 0.036 1.48+/−0.64 1.53+/−0.71 0.72
Sleep Medications 0.28+/−0.80 1.51+/−1.44 <0.001 1.43+/−1.41 1.68+/−1.49 0.43
Daytime Dysfunction 0.66+/−0.72 0.92+/−0.78 0.11 0.91+/−0.73 1.00+/−0.89 0.61
ISI Insomnia Severity Index, PSQI Pittsburgh Sleep Quality Index
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Pittsburgh sleep quality index
A total of 111 patients and 29 controls completed the PSQI
(Table 1). The total PSQI was higher in patients than controls
(7.2+/−3.8 vs. 4.9+/−3.4, p = 0.004), with the proportion of
abnormal PSQI higher in RBD patients than controls (68.5% vs.
44.9%, p = 0.029). On subcomponent analysis, this difference
was mainly driven by the ‘sleep disturbance’ (1.49+/−0.65, vs.
1.21+/−0.56, p = 0.035) and especially ‘sleep medications’ compo-
nents (1.51+/−1.43 vs. 0.28+/−0.80). These subscales query
symptoms of RBD itself and possible prodromal PD (see
discussion). There was no clear difference in PSQI insomnia items;
however, sleep maintenance insomnia is not directly queried in
the PSQI.
Of the 111 patients, 101 patients had at least one prospective
follow-up visit (Fig. 1, Table 1). We found no difference in
baseline PSQI scores between those who converted and those
who did not (7.1+/−3.8 in convertors vs. 7.7+/−4.1 in disease-free,
p = 0.52). Similarly, there was no significant difference in any
subcomponent between those who converted or remained
disease-free.
A total of 58 patients had a follow-up PSQI, conducted a mean
2.8 years after the first PSQI (Table 2). For the entire group, there was
no significant change in the total PSQI over time (change = −0.02
+/−3.08 points), or in any subcomponent of the PSQI. When looking
at those who converted to disease, there was no significant change
in total PSQI (change =−0.82+/−3.6, p = 0.36). However, self-
reported sleep duration increased significantly over time in those
destined to develop disease (+0.88+/−1.32 h, p = 0.014). This change
was significantly different from those who remained disease-free
(disease-free = −0.02+/−1.26 h, p = 0.023). The increased duration
was accompanied by a significant improvement in the PSQI sleep
duration score (−0.44+/−0.66, p = 0.014) and better sleep efficiency
(−0.44+/−0.81, p = 0.040), changes that were also significantly
different from those patients who remained disease-free (sleep
duration change in disease-free = 0.086+/−0.76, p = 0.012, efficiency
change = +0.18+/−1.19, p = 0.026).
a b
c d
Fig. 1 Shown is the Kaplan–Meier plot of disease-free survival of patients with idiopathic RBD, stratified according to the presence of sleep
abnormalities: a Sleepiness, as assessed with the ESS, b insomnia as assessed with the Insomnia Sleep Index, c general sleep disturbance, as
assessed with the PSQI, and d tonic REM, stratified to greater or less than 50% of epochs. The HR is for Cox regression analysis, adjusted for
age and sex
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Polysomnogram
We analzyed polysomnographic data for 151 patients and 85
controls (Table 3). There was no difference in sleep duration, sleep
efficiency, or % of stages N1, N3, or REM sleep between patients
and controls. A modest decrease in Stage 2 was seen in RBD
patients (61.9+/−11.6 vs. 65.5+/−9.3, p = 0.015). As expected, there
were large differences in REM tone measures between patients
and controls.
Within RBD patients, comparing results according to disease
outcome, there was no difference in total sleep time, sleep
efficiency, or proportion of time spent in Stage 1, 2, or slow wave
sleep between those who converted to disease vs. those who did
not (Table 3, Fig. 1). Convertors had a modest decrease in %
of sleep spent in REM sleep (15.8+/−8.0% vs. 19.8+/−7.5%,
pp = 0.005). Also, patients who converted had higher tonic REM
% (58.4+/−27.0% vs. 46.1+/−30.4%, p = 0.019), without any
difference in phasic REM% (35.5+/−17.0% vs. 34.7+/−18.0%,
p = 0.81). On Cox regression analysis adjusting for age and sex,
having a tonic REM > 50% was associated with a hazard ratio (HR)
of 1.88 for development of neurodegenerative disease (p = 0.039).
DISCUSSION
The key finding of this study was that although patients had mild
increase in ISI and PSQI scores compared to controls, neither
either excessive daytime somnolence nor insomnia predicted
disease outcome in patients with idiopathic RBD. On prospective
follow-up, we observed over time a subtle increase in sleep
duration and decreasing complaints of insomnia specifically in
patients destined to develop defined neurodegenerative disease.
With regards to daytime somnolence, we found a clearly
negative result. ESS scores were similar in RBD as controls, did not
increase over time, and did not predict outcome in idiopathic RBD.
Note that our results are in contrast to a previous study on ESS in
RBD, which found elevated ESS scores and a modest degree of
predictive value, such that those with scores > 8 had a faster
conversion time to neurodegenerative synucleinopathy.19 We
cannot easily explain the discrepancy in results. There may be
population and selection differences in the cohorts, or cohorts
may answer questionnaires differently.
Results of the other two scales are less clear. At baseline, we
found an elevation in both PSQI and ISI scores in idiopathic RBD
patients compared to controls. However, the etiology of the
increase is unclear. For the PSQI, the increase was mainly driven by
the sleep disturbance and sleep medication components. Note
that the sleep disturbance component contains questions possibly
related to RBD itself (i.e. ‘bad dreams’), and several questions that
may be confounded by other prodromal PD symptoms (nocturia,
pain, and temperature disturbance).22 The sleep medication
component would identify medications used as primary treatment
of RBD (i.e. clonazepam, melatonin) and approximately 50% were
taking one of these medications at baseline. The fact that there
was no increase in the components of subjective sleep quality,
sleep latency, duration, efficiency or daytime dysfunction suggests
that primary insomnia and somnolence on the PSQI are not
abnormal in idiopathic RBD. Similarly, on the ISI, most of the
elevated scores were in the general sleep disturbance/satisfaction
items, which may be related to symptoms of RBD itself. However,
unlike the PSQI, the ISI specifically queries sleep maintenance
insomnia. Here, we found a modest increase in idiopathic RBD
patients. It is possible that some sleep maintenance problems can
be directly due to RBD (i.e. wakening from agitated dreams). So, in
summary, we did not find unequivocal evidence that insomnia
per se is a prodromal feature of PD/DLB in RBD.
With regards to polysomnographic results, we confirmed our
previous report that patients with more severe REM atonia loss
were at higher risk of conversion to defined neurodegeneration.14
The fact that loss of REM atonia is progressive in RBD23 might
suggest that patients with higher loss are more advanced in their
disease, and therefore convert sooner (note, however, that follow-
up duration did not differ between convertors and non-
convertors). As in our previous publication, only tonic REM, but
not phasic REM, was associated with disease conversion. It is
unclear why this difference occurs. It is possible that there is a
small subset of patients diagnosed with RBD mainly because of
increased phasic REM, who have a form of RBD not related to
underlying neurodegenerative synucleinopathy. Given the fact
that the large majority of patients in our cohort converted to
neurodegenerative disease, however, this proportion is likely quite
small. On polysomnogram analysis, we also saw a slightly lower
proportion of time spent in REM sleep in those who converted to
defined neurodegenerative disease than those who remained
disease-free. These differences were modest, and the etiology
unclear, particularly given that control values were intermediate
between the two groups. The possibility of a spurious finding
needs to be considered. It is also possible that the more severe
loss of tonic REM in convertors made definition of the REM Stage
more difficult, thereby falsely reducing REM sleep scoring.
The assessment of evolution of sleep symptoms over time
found some intriguing results. Overall, neither insomnia nor
somnolence worsened over time in RBD. In contrast, insomnia
scores reduced, and patients destined to develop disease reported
increasing sleep duration over time. Some of the change in scales
may be due to improvement in non-insomnia symptoms; for
example, we have often informally noted spontaneous improve-
ment in RBD symptoms as patients develop neurodegenerative
disease. However, this should not explain the change in sleep
duration. We do not think that this resulted from adding sedative
medications. Of the 63 patients who had repeat ISI scores, 29 were
taking clonazepam or melatonin at baseline, and 35 at follow-up;




















Onset Insomnia −0.064+/−1.10 0.65 −0.15+/−1.22 0.59
Maintenance Insomnia −0.21+/−1.57 0.30 −0.45+/−1.05 0.083
Sleep Satisfaction −0.33+/−1.35 0.056 −0.60+/−1.43 0.076
Daytime Impact −0.17+/−1.06 0.22 −0.05+/−1.05 0.83
QOL impact −0.17+/−1.1 0.21 −0.10+/−1.2 0.71








Bed Time −0:02+/−0:48 0.79 −0:06+/−0:43 0.58
Wake Time +0:07+/−1:04 0.42 0:01+/−0:42 0.93
Sleep Duration (hours) +0.24+/−1.34 0.18 +0.88+/−1.32 0.014
Subcomponents Sleep
Latency
+0.12+/−1.30 0.48 −0.18+/−1.01 0.47
Sleep Quality 0.00+/−1.01 1.0 −0.059+/−1.39 0.86
Sleep Duration −0.069+/−0.76 0.49 −0.44+/−0.66 0.014
Sleep Inefficiency 0.00+/−1.13 1.0 −0.44+/−0.81 0.040
Sleep Disturbance −0.12+/−0.79 0.25 −0.24+/−0.75 0.21
Sleep Medications −0.06+/−0.73 0.49 +0.35+/−1.37 0.31
Daytime Dysfunction −0.017+/−3.08 0.53 −0.82+/−3.55 0.36
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therefore, only 6/63 had new sedative medications. Average doses
did not change over time in those taking clonazepam or
melatonin (Clonazepam dose = 0.99+/−0.68 mg/day baseline and
1.11+/−0.88mg last follow-up, Melatonin = 5.6+/−3.3 mg/day
baseline and 6.1+/−3.5 mg at follow-up). Moreover, there was no
correlation between change in ISI and change in these medica-
tions (Spearman correlation co-efficient = 0.07, p = 0.59). One
might speculate that a general increase in sleep drive occurs as
patients approach defined neurodegenerative disease, which
remains below the threshold of excessive somnolence/involuntary
daytime sleep. As neurodegeneration progresses (and perhaps
with addition of symptomatic PD medications), this increased
drive could progress to identifiable somnolence. Further studies
are required to see if somnolence itself has a prodrome of a
subthreshold increase in sleep drive.
Some limitations of the study should be noted. First, sleep
questionnaires were gathered in an ad-hoc clinical fashion until
2013; therefore, many patients did not have a full questionnaire
panel assessed. Nevertheless, we were able to obtain at least one
completed questionnaire on 80% of our participants. Second, it
should be noted that not all PD/DLB patients have RBD (RBD
can be found in 30–50% of PD patients and > 75% of DLB
patients).24–26 Because RBD marks a ‘diffuse-malignant’ subtype of
PD with increased dementia and autonomic features,27, 28 and
marks a subtype of DLB with decreased survival,29 our results
cannot be reliably generalized to all PD/DLB patients. One might
speculate that the RBD subtype may be more prone to
somnolence rather than insomnia (given that somnolence
commonly occurs in PD dementia and DLB), if so, population-
based cohorts might be more likely to find sleep maintenance
insomnia as a prodromal feature. Third, although the question-
naires are designed to assess specific syndromes, RBD itself can
affect the way they are answered; for this reason, we took care to
not simply report total scores at face value, but to look specifically
within questionnaires for components that directly assessed
insomnia or somnolence. Fourth, studies in idiopathic RBD may
be confounded by floor effects (as we have observed in studies of
autonomic dysfunction in RBD).30, 31 That is, if essentially all
patients with RBD are in prodromal stages of neurodegeneration
and the assessed marker becomes abnormal earlier in disease
than RBD, the predictive value may not be observable. However, a
floor effect is very unlikely here, given that scores were mostly
similar between RBD patients and controls. Fifth, we assessed
multiple outcomes in this study; the findings of increased sleep
duration and reduced sleep maintenance insomnia in convertors
were secondary variables, and should be considered as explora-
tory in nature.32 Finally, all our sleep measures are self-reported;
self-reports of sleepiness in particular may be prone to under-
estimation by patients.33 It is possible that querying caregivers
about somnolence would have given different results.
In conclusion, we did not find that somnolence or insomnia
were prodromal markers of PD and DLB in idiopathic RBD. In RBD,
there may be a subtle increase in sleep drive/duration that occurs
as patients develop defined neurodegeneration.
METHODS
Details of the cohort, diagnostic criteria and annual follow-up protocol
have been described in detail elsewhere.20, 34–36 The study was approved
by the ethics board of the Sacre Coeur hospital, and all patients gave
written informed consent to participate. Briefly, all patients had idiopathic
RBD, as confirmed by polysomnography. All patients were free of
parkinsonism and dementia at baseline. A comprehensive baseline
evaluation by a neurologist (R.B.P.), and neuropsychological examination
was performed, to examine markers of prodromal PD. Patients were then
followed annually with the same protocol. On follow-up, diagnosis of
parkinsonism was made according to UK brain bank and MDS criteria,21, 37
and the likeliest underlying diagnosis (i.e. PD or multiple system atrophy)
was determined by a movement disorders specialist (R.B.P.). Dementia was
diagnosed according to MDS criteria38 based on a consensus between the
neurologist (R.B.P.) and the neuropsychologist (J.F.G.).
Age and sex-matched control subjects were selected from our previous
cohort studies.30 All controls had polysomnography confirming the
absence of RBD, and had the same baseline evaluation performed as
idiopathic RBD patients. All were free of parkinsonism or dementia.
Polysomnogram was performed according to standard protocol, with
analysis of stages and quantification of REM atonia performed as described
in detail elsewhere.36
Three sleep measures were assessed. The ISI is a 7-item questionnaire;
the first three questions directly query sleep onset and sleep maintenance
insomnia, whereas the latter four query sleep satisfaction and impact of
sleep disorders on quality of life.39 A cutoff of 10 is considered as indicating
insomnia. The PSQI is a 25-item inventory that queries habitual bed time
and wake time (allowing assessment of circadian rhythm disturbance),
with seven additional subcomponents: subjective sleep quality, sleep
latency, sleep duration, sleep efficiency, various sources of sleep
disturbance, sleep medication, and daytime dysfunction (somnolence
and apathy).40 A cutoff score of five on the total index is used to define
abnormal sleep. The ESS is a test for somnolence that queries the
propensity to fall asleep in eight different situations.41 A cutoff of 10 is
used to define pathologic sleepiness. We assessed these scales are part of
the clinical assessment (until 2013, not all patients completed these scales).
After 2013, sleep questionnaires were also assessed systematically as part
of the research evaluation.
Analysis
For comparison to controls, the first available baseline questionnaire
(always in the idiopathic RBD state) was assessed in all patients. Total
scores for each scale was used as the primary analysis; secondary analysis
included scale subcomponents. To assess predictive value of sleep
disorders, all patients who had baseline evaluation and at least one
annual follow-up examination were included. The primary analysis was for
the scores as continuous variables, using student t-test. Categorical
variables (i.e. proportion abnormal) were assessed with Fischer Exact test.
We also assessed predictive value of sleep variables using Cox regression
Table 3. Polysomnographic variables
Control (n= 85) Idiopathic RBD (n= 151) p Disease-free Converted p
Sleep Latency (min) 19.1+/−24.4 23.7+/−24.8 0.17 21.8+/−22.7 28.4+/−30.4 0.18
Total Sleep Time (min) 383.2+/−63.4 384.3+/−61.7 0.90 389.5+/−57.5 373.8+/−71.6 0.19
Sleep efficiency (%) 79.6+/−12.3 81.8+/−10.6 0.15 82.7+/−9.5 79.8+/−12.3 0.15
Stage 1 % 12.2+/−6.8 13.1+/−9.2 0.43 13.1+/−8.4 13.8+/−11.4 0.71
Stage 2 % 65.5+/−9.3 61.9+/−11.6 0.015 60.9+/−11.0 63.2+/−12.6 0.29
Slow wave % 5.4+/−8.1 6.5+/−8.3 0.33 7.2+/−0.79 7.1+/−9.4 0.48
REM % 16.9+/−4.8 18.5+/−7.9 0.09 19.8+/−7.5 15.8+/−8.0 0.006
Phasic REM density % 11.5+/−7.9 (n= 59) 36.6+/−17.6 <0.001 35.5+/−17.0 34.7+/−18.0 0.81
Tonic REM % 7.9+/−9.0 (n= 59) 51.4+/−29.6 <0.001 46.1+/−30.4 58.4+/−27.0 0.019
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also adjusting for age and sex. Finally, for all patients who filled out
repeated questionnaires, we assessed change over time comparing the
most recently-measured scores to baseline, using one-sample t-test (we
analyzed polysomnogram variables at baseline only).
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